Anatomical main group
C – KARDIOVASKULÄRES SYSTEM
35Decisions
54Patient groups
Added benefit by patient group
- Major1
- Considerable2
- Minor5
- Non-quantifiable5
- Not proven41
Subgroups
- C01 HERZTHERAPIE 6 decisions
- C02 ANTIHYPERTENSIVA 7 decisions
- C03 DIURETIKA 2 decisions
- C07 BETA-ADRENOZEPTORANTAGONISTEN 1 decision
- C09 MITTEL MIT WIRKUNG AUF DAS RENIN-ANGIOTENSIN-SYSTEM 4 decisions
- C10 MITTEL, DIE DEN LIPIDSTOFFWECHSEL BEEINFLUSSEN 15 decisions
Decisions, newest first
- 2026-08-06WinrevairSotaterceptNon-quantifiable
- 2026-05-21TryngolzaOlezarsenMinor
- 2025-09-18BeyonttraAcoramidisNot proven
- 2025-03-06WinrevairSotaterceptMinor
- 2025-02-06FilspariSparsentanMinor
- 2024-07-04EvkeezaEvinacumabNot proven
- 2024-07-04EvkeezaEvinacumabNot proven
- 2024-06-06PraluentAlirocumabNot proven: 2 of 2 patient groups
- 2024-02-01CamzyosMavacamtenConsiderable
- 2023-12-21AdempasRiociguatNot proven
- 2023-12-07EntrestoSacubitril/ValsartanNot proven
- 2023-08-17KerendiaFinerenonNon-quantifiable
- 2023-08-17KerendiaFinerenonNot proven
- 2022-06-16RepathaEvolocumabNot proven: 4 of 4 patient groups
- 2022-05-05VazkepaIcosapent-EthylNot proven
- 2022-03-03VerquvoVericiguatMinor
- 2022-01-06GiaprezaAngiotensin-II-AcetatNot proven
- 2021-07-15LeqvioInclisiranNot proven: 2 of 2 patient groups
- 2021-04-15NustendiBempedoinsäure/EzetimibNot proven: 2 of 2 patient groups
- 2021-04-15NilemdoBempedoinsäureNot proven: 2 of 2 patient groups
- 2020-09-03AdempasRiociguatNot proven
- 2020-09-03AdempasRiociguatNot proven
- 2020-02-20WaylivraVolanesorsenNon-quantifiable
- 2019-08-01NamusclaMexiletinNon-quantifiable
- 2019-05-02PraluentAlirocumabNot proven: 4 of 4 patient groups
- 2018-09-06RepathaEvolocumabNot proven: 3 of 3 patient groups
- 2017-04-06OpsumitMacitentanNot proven
- 2016-12-15UptraviSelexipagNot proven
- 2016-06-16EntrestoSacubitril/ValsartanConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2016-05-04PraluentAlirocumabNot proven
- 2016-03-09RepathaEvolocumabNot proven: 4 of 4 patient groups
- 2015-11-27LojuxtaLomitapidNot proven: 3 of 3 patient groups
- 2015-02-19HemangiolPropranololMajor: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2012-03-29RapiscanRegadenosonNot proven
- 2012-03-15EdarbiAzilsartan MedoxomilNot proven
Data status: 2026-10-29